June 10, 2025 a 07:43 pm
GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.
Gilead Sciences, Inc. is a leading biopharmaceutical company with a diverse portfolio in the field of unmet medical needs. Despite challenges in the sector, GILD has shown resilience through strategic collaborations and innovation in treatment areas such as HIV/AIDS and liver diseases. The current forecast indicates moderate growth potential, balancing risks and opportunities.
Fundamental Rating
The fundamental analysis reflects a balanced outlook with competitive scores in key financial metrics. The overall sentiment grades Gilead with a 'B+', indicating a stable performance with potential upside.
| Category | Score | Score Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
Gilead's historical performance reflects a consistent score, indicating steady business operations and financial health over time.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-06-10 | 3 | 5 | 5 | 5 | 1 | 2 | 1 |
| Previous | 0 | 5 | 5 | 5 | 1 | 2 | 1 |
Analyst Price Targets
Analyst projections suggest a positive price target range with the median price indicating moderate stock growth. The sentiment remains bullish.
| High | Low | Median | Consensus |
|---|---|---|---|
| $132 | $83 | $126 | $119.2 |
Analyst Sentiment
The current analyst sentiment represents a 'Buy' consensus with a strong inclination towards positive recommendations.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 23 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Gilead Sciences, Inc. remains a strong player in the biopharmaceutical industry, recognized for its innovation and broad product range. The consistent financial scores and positive analyst sentiments suggest stable growth potential. However, dependencies on specific products and market volatility pose potential risks. Overall, Gilead offers a solid investment opportunity with balanced risk-reward dynamics for stakeholders.